SCHEMBL5814814

SCHEMBL5814814

CCOC(=O)C1=C(C)NC2=C(C(=O)CCC2)C1C

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 15/20 0.60
ALDH1A1 P00352 11/20 0.60
HSD17B10 Q99714 7/20 0.60
HPGD P15428 4/20 0.60
TSHR P16473 1/20 0.60
CASP1 P29466 3/20 0.58
CASP7 P55210 3/20 0.58
GAA P10253 2/20 0.58
LMNA P02545 2/20 0.56
HTT P42858 1/20 0.56
MAPK1 P28482 2/20 0.55
CYP1A2 P05177 1/20 0.55
CYP2C9 P11712 1/20 0.55
CYP2C19 P33261 1/20 0.55
FFAR3 O14843 1/20 0.53
ALOX15 P16050 1/20 0.52
SMN1; SMN2 Q16637 3/20 0.51
BAP1 Q92560 1/20 0.48
TP53 P04637 1/20 0.48
POLB P06746 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5815734 0.87 KDM4E (0.53) KDM4EALDH1A1HSD17B10HPGDTSHR
SCHEMBL6027133 0.80 HTT (0.69) KDM4EALDH1A1HSD17B10HPGDTSHR
SCHEMBL13998207 0.78 FFAR3 (0.49) KDM4EALDH1A1HSD17B10HPGDTSHR
SCHEMBL6027471 0.78 KDM4E (0.54) KDM4EALDH1A1HSD17B10HPGDTSHR
SCHEMBL3320549 0.78 KDM4E (0.77) KDM4EALDH1A1HSD17B10HPGDTSHR
SCHEMBL3326941 0.78 KDM4E (0.77) KDM4EALDH1A1HSD17B10HPGDTSHR
SCHEMBL3323430 0.77 KDM4E (0.76) KDM4EALDH1A1HSD17B10HPGDTSHR
SCHEMBL3000060 0.76 KDM4E (0.68) KDM4EALDH1A1HSD17B10HPGDTSHR
SCHEMBL15765866 0.76 KDM4E (0.72) KDM4EALDH1A1HSD17B10HPGDTSHR
SCHEMBL3325204 0.76 KDM4E (1.00) KDM4EALDH1A1HSD17B10HPGDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1663227-A2 DIHYDROPYRIDINE COMPOUNDS FOR TREATING OR PREVENTING METABOLIC DISORDERS Synta Pharmaceuticals Corporation (US) 2006-06-07 EP claimed
US-20050203119-A1 Dihydropyridine compounds for treating or preventing metabolic disorders SYNTA PHARMACEUTICAL CORP. 2005-09-15 US claimed
WO-2005025507-A2 DIHYDROPYRIDINE COMPOUNDS FOR TREATING OR PREVENTING METABOLIC DISORDERS SYNTA PHAMACEUTICALS CORP. (US) 2005-03-24 WO claimed
WO-2006065842-A2 5,6,7,8-TETRAHYDROQUINOLINES AND RELATED COMPOUNDS AND USES THEREOF SYNTA PHARMACEUTICALS CORP. (US) 2006-06-22 WO disclosed
EP-1663227-A2 DIHYDROPYRIDINE COMPOUNDS FOR TREATING OR PREVENTING METABOLIC DISORDERS Synta Pharmaceuticals Corporation (US) 2006-06-07 EP disclosed
US-20050203119-A1 Dihydropyridine compounds for treating or preventing metabolic disorders SYNTA PHARMACEUTICAL CORP. 2005-09-15 US disclosed
WO-2005025507-A2 DIHYDROPYRIDINE COMPOUNDS FOR TREATING OR PREVENTING METABOLIC DISORDERS SYNTA PHAMACEUTICALS CORP. (US) 2005-03-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050203119-A1 Dihydropyridine compounds for treating or preventing metabolic disorders SLC5A2, SLC5A1, QDPR KDM4E 2337/4885ALDH1A1 416/4885HSD17B10 447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.